Updated study results of pelcitoclax (APG-1252) combined with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Ma, Y. [1 ]
Zhao, H. [1 ]
Zhao, Y. [2 ]
Cheng, Y. [3 ]
Cui, J. [4 ]
Liu, G. [5 ]
Xiong, D. [6 ]
Zhang, J. [5 ]
Xu, L. [7 ]
Yu, J. [5 ]
Men, L. [7 ]
Liang, E. [8 ]
Yang, D. [5 ]
Zhang, L. [1 ]
Zhai, Y. [9 ]
机构：
[1] Sun Yat Sen Univ, Dept Med Oncol, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China,Canc Ctr, Guangzhou, Peoples R China
[2] Zhengzhou Univ, Dept Med Oncol, Henan Canc Hosp, Canc Hosp, Zhengzhou, Peoples R China
[3] Jilin Canc Hosp, Dept Med Thorac Oncol, Changchun, Peoples R China
[4] First Hosp Jilin Univ, Dept Oncol, Changchun, Peoples R China
[5] Ascentage Pharma Suzhou Co Ltd, Clin Res, Suzhou, Peoples R China
[6] Ascentage Pharma Suzhou Co Ltd, Preclin Res & Bio markers, Suzhou, Peoples R China
[7] Ascentage Pharma Suzhou Co Ltd, Biostat, Suzhou, Peoples R China
[8] Ascentage Pharma Grp Inc, Preclin Res & Biomarkers, Rockville, MD USA
[9] Ascentage Pharma Grp Inc, Clin Res, Rockville, MD USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2351
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1317MO
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non-small cell lung cancer (NSCLC).
    Zhang, Li
    Zhao, Hongyun
    Zhao, Yanqiu
    Cheng, Ying
    Cui, Jiuwei
    Ma, Yuxiang
    Yang, Chen
    Zhang, Jie
    Xu, Liang
    Yu, Juan
    Men, Lichuang
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.
    Yang, James Chih-Hsin
    Cho, Byoung Chul
    Kim, Dong-Wan
    Kim, Sang-We
    Lee, Jong-Seok
    Su, Wu-Chou
    John, Tom
    Kao, Stephen Chuan-Hao
    Natale, Ronald
    Goldman, Jonathan Wade
    Overend, Philip
    Vishwanathan, Karthick
    Ye, Xin
    Yang, Zhenfan
    Ahn, Myung-Ju
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [3] Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC
    Zhang, L.
    Zhao, H.
    Ma, Y.
    Cheng, Y.
    Zhao, Y.
    Cui, J.
    Yang, C.
    Zhang, J.
    Wang, P.
    Xu, L.
    Yu, J.
    Men, L.
    Liang, E.
    Yang, D.
    Zhai, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S891 - S891
  • [4] CARDIOVASCULAR EVENTS IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER ON OSIMERTINIB
    Peleg, Ariel
    Ibtida, Ishmam
    Liu, Jennifer
    Steingart, Richard
    Yu, Anthony
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 3288 - 3288
  • [5] Osimertinib in EGFR-mutant non-small cell lung carcinoma
    Lorenz, Judith
    PNEUMOLOGIE, 2023, 77 (11): : 847 - 847
  • [6] Tackling Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer
    Blaquier, Juan Bautista
    Ortiz-Cuaran, Sandra
    Ricciuti, Biagio
    Mezquita, Laura
    Cardona, Andres Felipe
    Recondo, Gonzalo
    CLINICAL CANCER RESEARCH, 2023, 29 (18) : 3579 - 3591
  • [7] A Phase II Trial of Neoadjuvant Osimertinib for Surgically Resectable EGFR-Mutant Non-Small Cell Lung Cancer: Updated Results
    Blakely, C.
    Urisman, A.
    Kerr, D.
    Wu, W.
    Bacaltos, B.
    Rotow, J.
    Gubens, M.
    Jones, K.
    Bivona, T.
    Joo, S.
    Riess, J.
    Aisner, D.
    Doebele, R.
    Patil, T.
    Schenk, E.
    Kratz, J.
    Jablons, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1039 - S1040
  • [8] First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC).
    Qin, Angel
    Kalemkerian, Gregory Peter
    Mohindra, Nisha Anjali
    Patel, Jyoti D.
    Karapetis, Christos Stelios
    Carlisle, Jennifer W.
    Sands, Jacob
    Spira, Alexander I.
    Gao, Bo
    Amin, Harshad
    Paudyal, Bishnuhari
    Frank, Genevieve
    Sun, Xuemei
    Xu, Yang
    Wang, Cunlin
    Fu, Tommy
    Winkler, Robert
    Liang, Zhiyan
    Yang, Dajun
    Zhai, Yifan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] INDIRECT COMPARISON OF EFFICACY AND SAFETY FOR AUMOLERTINIB VS OSIMERTINIB IN PATIENTS WITH EGFR-MUTANT NON-SMALL CELL LUNG CANCER (NSCLC)
    Stergiopoulos, S.
    King, S.
    Curtis, M.
    Dillon, S. A.
    Akehurst, R.
    Lee, D.
    Guelfucci, F.
    Ngami, A.
    Bianic, F.
    Li, Y.
    Ma, X.
    Ali, S.
    Miller, V. A.
    Popat, S.
    VALUE IN HEALTH, 2022, 25 (12) : S42 - S42
  • [10] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ortega-Franco, Ana
    Rafee, Shereen
    ONCOLOGY AND THERAPY, 2022, 10 (01) : 13 - 22
12345